The antineoplastic efficacy of the prodrug cloretazine™ is produced by the synergistic interaction of carbamoylating and alkylating products of its activation

Oncology Research

Volumn 15, Issue 6, 2005, Pages 313-325

  Baumann, Raymond P ^a   Seow, Helen A ^a   Shyam, Krishnamurthy ^a   Penketh, Philip G ^a   Sartorelli, Alan C ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AGT; Carbamoylation; Chloroethylation; Cloretazine ; Sulfonylhydrazine prodrugs

Indexed keywords

1,2 BIS(METHYLSULFONYL) 1 METHYLHYDRAZINE; 1,2 BIS(METHYLSULFONYL) 1 [(2 CHLOROETHYL) 2 (METHYLAMINO)CARBONYL]HYDRAZINE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLORETAZINE; DNA; HYDRAZINE DERIVATIVE; KS 90; METHYL ISOCYANATE; METHYLNITROSOUREA; MITOMYCIN C; PRODRUG; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CHO CELL; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; X IRRADIATION;

EID: 30444446785     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504005776404553     Document Type: Article

References (25)

1. Shyam, K.; Penketh, P. G.; Divo, A. A.; Loomis, R. H.; Rose, W. C.; Sartorelli, A. C. Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J. Med. Chem. 33:2259-2264; 1990.
2. Shyam, K.; Penketh, P. G.; Divo, A. A.; Loomis, R. H.; Rose, W. C.; Sartorelli, A. C. Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2- (2-chloroethyl)hydrazines as antineoplastic agents. J. Med. Chem. 36:3496-3502; 1993.
3. Shyam, K.; Penketh, P. G.; Loomis, R. H.; Rose, W. C.; Sartorelli, A. C. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J. Med. Chem. 39:796-801; 1996.
4. Finch, R. A.; Shyam, K.; Penketh, P. G.; Sartorelli, A. C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)-carbonylhydrazine (101M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res. 61:3033-3038; 2001.
5. Giles, F.; Thomas, D.; Garcia-Manero, G.; Faderl, S.; Cortes, J.; Verstovsek, S.; Ferrajoli, A.; Jeha, S.; Beran, M.; Koller, C.; Andreeff, M.; Cahill, A.; Clairmont, C.; Sznol, M.; Kantarjan, F. A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin. Cancer Res. 10: 2908-2917; 2004.
6. Penketh, P. G.; Shyam, K.; Sartorelli, A. C. Comparison of DNA lesions produced by tumor inhibitory 1,2-bis(sulfonyl)-hydrazines and chloroethylnitrosoureas. Biochem. Pharmacol. 59:283-291; 2000.
7. 6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated during the decomposition of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP 40101M). Cancer Chemother. Pharmacol. 53:279-287; 2004.
8. Baril, B. B.; Baril, E. F.; Lazlo, J.; Wheeler, G. P. Inhibition of rat liver DNA polymerase by nitrosoureas and isocyanates. Cancer Res. 35:1-5; 1975.
9. Rice, K. P.; Penketh, P. G.; Shyam, K.; Sartorelli, A. C. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine™ and BCNU. Biochem. Pharmacol. 69: 1463-1472; 2005.
10. Petak, I.; Mihalik, R.; Bauer, P. I.; Suli-Vargha, H.; Sebestyen, A.; Kopper, L. BCNU is a caspase-mediated inhibitor of drug-induced apoptosis. Cancer Res. 58:614-618; 1998.
11. Kann, H. H.; Kohn, K. W.; Lyles, J. M. Inhibition of DNA repair by 1,3-bis(2-chloroethyl)-1-nitrosourea breakdown product, 2-chloroethyl isocyanate. Cancer Res. 34:398-402; 1974.
12. Colvin, M.; Brundrett, R. B.; Cowens, J. W.; Jardine, I.; Ludlum, D. B. A chemical basis for the antitumor activity of the chloroethylnitrosoureas. Biochem. Pharmacol. 25: 695-699; 1976.
13. Panasci, L. C.; Green, D.; Nagourney, R.; Fox, P.; Schein, P. S. A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice. Cancer Res. 37:2615-2618; 1977.
14. Gibson, N. W.; Hickman, J. A. The role of isocyanates in the toxicity of antitumor haloalkylnitrosoureas. Biochem. Pharmacol. 31:2795-2800; 1982.
15. Schallreuter, K. U.; Gleason, F. K.; Wood, J. M. The mechanism of action of the nitrosourea antitumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim. Biophys. Acta 1054:14-20; 1990.
16. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol. 51:167-223; 1995.
17. 6-alkylguanine-DNA alkytransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50: 6119-6129; 1990.
18. Gerson, S. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20:2388-2399; 2002.
19. Gerson, S. L. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4:296-307; 2004.
20. Baumann, R. P.; Hodnick, W. F.; Seow, H. A.; Belcourt, M. F.; Rockwell, S.; Sherman, D. H.; Sartorelli, A. C. Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res. 61:7770-7776; 2001.
21. 6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother. Pharmacol. 53:288-295; 2004.
22. Mitra, S.; Kaina, B. Regulation of repair of alkylation damage in mammalian genomes. Prog. Nucleic Acids Res. Mol. Biol. 44:109-142; 1993.
23. Konca, K.; Lankoff, A.; Banasik, A.; Lisowska, H.; Kuszewski, T.; Gozdz, S.; Koza, Z.; Wojcik, A. A cross-platform public domain PC image-analysis program for the comet assay. Mut. Res. 534:15-20; 2003.
24. Zainol, M.; Almeida, G. M.; Sherwood, B. T.; Bowman, K. J.; Jones, G. D. D. Development of an internal standard for the comet assay: Minimizing intra- and inter-experiment variability in the measures of DNA damage formation and repair. Proc. Am. Assoc. Cancer Res. 46:835; 2005.
25. Kornblau, S. M.; Qui, Y. H.; Cade, J. S.; Lemker, E. M.; Giles, F. Survivor cells predict which patient will respond to therapy with VNP40101M and ara-C. Blood 104:abstract 2027; 2004.